131 related articles for article (PubMed ID: 19615745)
1. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
Breccia M; Alimena G
Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
[No Abstract] [Full Text] [Related]
2. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
Cashen A; DiPersio JF; Khoury H
J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
[No Abstract] [Full Text] [Related]
3. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
4. Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?
Song MK; Chung JS; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ
Leuk Res; 2009 Nov; 33(11):1459-62. PubMed ID: 19446878
[TBL] [Abstract][Full Text] [Related]
5. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
6. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital.
Reksodiputro AH; Syafei S; Prayogo N; Karsono B; Rinaldi I; Rajabto W; Mulansari NA
Acta Med Indones; 2010 Jan; 42(1):2-5. PubMed ID: 20305324
[TBL] [Abstract][Full Text] [Related]
8. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
9. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
10. STI-571 (Gleevec) in the treatment of chronic myeloid leukaemia.
Kumar L; Kumari M; Menon H
Natl Med J India; 2002; 15(5):298. PubMed ID: 12502149
[No Abstract] [Full Text] [Related]
11. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
Smith BD
J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
[No Abstract] [Full Text] [Related]
12. Pure red cell aplasia in a patient of chronic granulocyte leukemia associated with imatinib.
Meng HT; Li Y; Jin J; Qian WB; Yang CM
Ann Hematol; 2007 Mar; 86(3):231-2. PubMed ID: 17123082
[No Abstract] [Full Text] [Related]
13. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
14. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Sneed TB; Kantarjian HM; Talpaz M; O'Brien S; Rios MB; Bekele BN; Zhou X; Resta D; Wierda W; Faderl S; Giles F; Cortes JE
Cancer; 2004 Jan; 100(1):116-21. PubMed ID: 14692031
[TBL] [Abstract][Full Text] [Related]
15. [Management of chronic myeloid leukemia by imatinib].
Kizaki M
Rinsho Ketsueki; 2010 Oct; 51(10):1377-85. PubMed ID: 20962470
[No Abstract] [Full Text] [Related]
16. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases.
Breccia M; Cannella L; Montefusco E; Frustaci A; Pacilli M; Alimena G
Leuk Res; 2008 Mar; 32(3):519-20. PubMed ID: 17804066
[No Abstract] [Full Text] [Related]
17. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
19. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
Mcpherson T; Sherman V; Turner R
J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
[No Abstract] [Full Text] [Related]
20. Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy.
Breccia M; Santopietro M; Loglisci G; Stagno F; Cannella L; Carmosino I; Alimena G
Leuk Res; 2010 Aug; 34(8):e224-5. PubMed ID: 20356624
[No Abstract] [Full Text] [Related]
[Next] [New Search]
